TSS
NRIX icon

Two Sigma Securities’s Nurix Therapeutics NRIX Stock Holding History

Two Sigma Securities’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,553
Closed -$179K – 2157
2026
Q1 		$179K Buy
+11,553
New +$192K 0.02% 1071

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Securities's NRIX Position: Q2 2026 in Review

Two Sigma Securities sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 11,553 shares — an estimated $179K sold.

Two Sigma Securities first reported a position in NRIX in Q1 2026 and held it in 1 quarter. The position peaked at $179K in Q1 2026. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Two Sigma Securities reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Two Sigma Securities sold 11,553 Nurix Therapeutics shares in Q2 2026, an estimated $179K.
  • Two Sigma Securities first reported a position in Nurix Therapeutics in Q1 2026 and held it in 1 quarter.
  • Two Sigma Securities's Nurix Therapeutics position peaked at $179K in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.